AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
19:14
Teachers' unions demand that Education Ministers pay the salary rights won in court
19:06
A female police officer in Constanța accidentally fired a shot at the institution’s headquarters
18:58
Isaac Herzog officially tasked Gadi Eisenkot with forming the government
18:39
Argentina: A suspect was arrested after allegedly threatening Pope Leo XIV with death
18:25
Two passenger trains collided in Egypt / Four people died and 88 were injured
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
